| Ytd | -29.95% | |
| 1y | -47.27% |
| Open | 1.45 | Prev Close | 1.44 | Low | 1.43 | High | 1.45 | Mkt Cap | 55.25M |
| Vol | 3.82K | Avg Vol | 89.19K | EPS | -0.05 | P/E | -28.69 | Forward P/E | N/A |
| Beta | 0.06 | Short Ratio | 4.64 | Inst. Own | 2.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.59 | 200-d Avg | 1.88 | 1yr Est | 7.00 |
OKYO News
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
Market breadth continues to improve, even if it has pulled back lately, according to Adam Turnquist,
Walt Disney Co (NYSE:DIS, XETRA:WDP) is scheduled to report fiscal third quarter results on August 5
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F f
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigat
LONDON and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinica
OKYO Pharma Ltd (NASDAQ:OKYO) announced on Monday that it has filed its annual report on Form 20-F f
HC Wainwright & Co. analyst Yi Chen maintains OKYO Pharma (NASDAQ:OKYO) with a Buy and lowers
Gainers Q32 Bio (NASDAQ:QTTB) stock moved upwards by 44.4% to $16.19 during Friday's after-mark
FDA alignment on a single-dose Phase 3 study design and potential single-trial registration pathway
On Wednesday, 216 stocks hit new 52-week lows.